Novartis AG (NVS:NYSE) closed at $151.12 on October 23, 2026, down 3.30% on the day. The stock trades 11.3% below its 52-week high of $170.46 and 24.3% above its 52-week low of $121.57. Over the past year, it gained 15.9%. Novartis AG is part of the Health Care sector (Major Pharmaceuticals).
In 252 trading sessions since October 23, 2025, NVS closed higher on 128 days (51%). Its best day was September 1, 2026 (+6.04%) and its worst was September 8, 2026 (-13.93%). The stock moved 10% or more in a single session 1 time. It opened at least 5% above the previous day's high 1 time.
Novartis AG researches, develops, manufactures, and markets a range of healthcare products worldwide. It operates through three segments: Innovative Medicines, Sandoz, and Alcon. The Innovative Medicines segment offers patented prescription medicines to enhance health outcomes for patients and health-care providers. It franchises ophthalmology, neuroscience, immunology and dermatology, respiratory, cardio-metabolic, and other medicines, as well as cell and gene therapies. The Sandoz segment offers active ingredients and finished dosage forms of pharmaceuticals for dermatology, respiratory and ophthalmic, cardiovascular, metabolism, central nervous system, pain, gastrointestinal, and hormonal therapies; active pharmaceutical ingredients and intermediates primarily antibiotics; protein or other biotechnology-based products; and cytotoxic products for the hospital markets, as well as biotechnology manufacturing services to other companies. The Alcon segment offers eye care products, including ophthalmic surgical equipment, instruments, disposable products, and intraocular lenses for use in surgical procedures to treat cataracts, vitreoretinal conditions, glaucoma, and refractive error...
Find more stocks like NVS with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.